Integrated omics analysis of non‐small‐cell lung cancer cells harboring the egfr c797s mutation reveals the potential of axl as a novel therapeutic target in tki‐resistant lung cancer

Oncogenic mutations of epidermal growth factor receptor (EGFR) are responsive to targeted tyrosine kinase inhibitor (TKI) treatment in non‐small‐cell lung cancer (NSCLC). However, NSCLC patients harboring activating EGFR mutations inevitably develop resistance to TKIs. The acquired EGFR C797S mutation is a known mechanism that confers resistance to third‐generation EGFR TKIs such as AZD9291. In this work, we employed CRISPR/Cas9 genome‐editing technology to knock‐in the EGFR C797S mutation into an NSCLC cell line harboring EGFR L858R/T790M. The established cell model was used to investigate the biology and treatment strategy of acquired EGFR C797S mutations. Transcriptome and proteome analyses revealed that the differentially expressed genes/proteins in the cells harboring the EGFR C797S mutation are associated with a mesenchymal-like cell state with elevated expression of AXL receptor tyrosine kinase. Furthermore, we presented evidence that inhibition of AXL is effective in slowing the growth of NSCLC cells harboring EGFR C797S. Our findings suggest that AXL inhibition could be a second‐line or a potential adjuvant treatment for NSCLC harboring the EGFR C797S mutation.